Identification of flavonoid C-glycosides as promising antidiabetics targeting protein tyrosine phosphatase 1B

Rampadarath, AthikaBalogun, Fatai OladunniPillay, CharleneSabiu, Saheed2024-02-152024-02-152022-06-24Rampadarath, A. et al. 2022. Identification of flavonoid C-glycosides as promising antidiabetics targeting protein tyrosine phosphatase 1B. Journal of Diabetes Research: 6233217-. doi:10.1155/2022/62332172314-67452314-6753 (Online)isidoc: 2R1YRpubmed: 35782627https://hdl.handle.net/10321/5148Protein tyrosine phosphatase 1B (PTP1B), a negative regulator of the insulin signaling pathway, has gained attention as a validated druggable target in the management of type 2 diabetes mellitus (T2DM). The lack of clinically approved PTP1B inhibitors has continued to prompt research in plant-derived therapeutics possibly due to their relatively lesser toxicity profiles. Flavonoid C-glycosides are one of the plant-derived metabolites gaining increased relevance as antidiabetic agents, but their possible mechanism of action remains largely unknown. This study investigates the antidiabetic potential of flavonoid C-glycosides against PTP1B in silico and in vitro. Of the seven flavonoid C-glycosides docked against the enzyme, three compounds (apigenin, vitexin, and orientin) had the best affinity for the enzyme with a binding score of -7.3 kcal/mol each, relative to -7.4 kcal/mol for the reference standard, ursolic acid. A further probe (in terms of stability, flexibility, and compactness) of the complexes over a molecular dynamics time study of 100 ns for the three compounds suggested orientin as the most outstanding inhibitor of PTP1B owing to its overall -34.47 kcal/mol binding energy score compared to ursolic acid (-19.24 kcal/mol). This observation was in accordance with the in vitro evaluation result, where orientin had a half maximal inhibitory concentration (IC50) of 0.18 mg/ml relative to 0.13 mg/ml for the reference standard. The kinetics of inhibition of PTP1B by orientin was mixed-type with V max and K m values of 0.004 μM/s and 0.515 μM. Put together, the results suggest orientin as a potential PTP1B inhibitor and could therefore be further explored in the management T2DM as a promising therapeutic agent.11 pElectronic-eCollectionen1116 Medical PhysiologyHumansDiabetes Mellitus, Type 2FlavonoidsGlycosidesEnzyme InhibitorsHypoglycemic AgentsProtein Tyrosine Phosphatase, Non-Receptor Type 1Diabetes Mellitus, Type 2Enzyme InhibitorsFlavonoidsGlycosidesHumansHypoglycemic AgentsProtein Tyrosine Phosphatase, Non-Receptor Type 1Identification of flavonoid C-glycosides as promising antidiabetics targeting protein tyrosine phosphatase 1BArticle2024-02-0910.1155/2022/6233217